Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quest Diagnostics/SmithKline Beecham

This article was originally published in The Gray Sheet

Executive Summary

Delay of Quest's $1.3 bil. acquisition of SB's clinical laboratory operations over the issue of SB's access to Quest's clinical lab information database (1"The Gray Sheet" July 12, In Brief) is resolved with Quest's granting to SB non-exclusive rights to use the database, Quest says Aug. 9. As part of the agreement, Quest will receive a minority interest in a company that SB will form to sell information products and services. The transaction is expected to close within two weeks

You may also be interested in...

Quest Diagnostics/SmithKline Beecham

Quest's acquisition of SB's clinical laboratory operations did not close on July 2, as had been previously expected, due to difficulties in finalizing an ancillary contract referred to as the definitive data access agreement. "The parties have been unable to agree on the extent to which SmithKline Beecham would have the right to commercialize information products utilizing Quest Diagnostics' laboratory data," according to a July 1 release. Quest shareholders approved the transaction June 29; either party can terminate the purchase agreement after Sept. 30, 1999, if the transaction has not closed (1"The Gray Sheet" Feb. 15, p. 27)

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts